Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
4don MSN
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
Like many pharma stocks, Eli Lilly (NYSE: LLY ... loss candidate it's suggested may be even more effective than its current drugs, and orforglipron, a weight loss candidate in pill form.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results